Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases.
about
Characterizing affinity epitopes between prion protein and β-amyloid using an epitope mapping immunoassayStructures of rat and human islet amyloid polypeptide IAPP(1-19) in micelles by NMR spectroscopyTargeting heat shock proteins to modulate α-synuclein toxicityAlzheimer's disease and insulin resistance: translating basic science into clinical applicationsEffect of the inhaled anesthetics isoflurane, sevoflurane and desflurane on the neuropathogenesis of Alzheimer's disease (review)Nodular goiter with amyloid deposition in an elderly patient: fine-needle cytology diagnosis and review of the literatureDynamic -Helix Structure of Micelle-bound Human AmylinNMR Structure in a Membrane Environment Reveals Putative Amyloidogenic Regions of the SEVI Precursor Peptide PAP 248−286PMEL Amyloid Fibril Formation: The Bright Steps of PigmentationAmyloid-β triggers the release of neuronal hexokinase 1 from mitochondriaProtection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomersHuman apolipoprotein A-I-derived amyloid: its association with atherosclerosisHuman apolipoprotein A-I natural variants: molecular mechanisms underlying amyloidogenic propensityAlzheimer's disease related markers, cellular toxicity and behavioral deficits induced six weeks after oligomeric amyloid-β peptide injection in ratsAmyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling.Insights into the folding and unfolding processes of wild-type and mutated SH3 domain by molecular dynamics and replica exchange molecular dynamics simulations.Dendritic and axonal mechanisms of Ca2+ elevation impair BDNF transport in Aβ oligomer-treated hippocampal neuronsDisease-associated mutant ubiquitin causes proteasomal impairment and enhances the toxicity of protein aggregates.Cognitive impairment in the Tg6590 transgenic rat model of Alzheimer's diseaseSimulation of two-dimensional ultraviolet spectroscopy of amyloid fibrils.Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disordersHigh-resolution bioelectrical imaging of Aβ-induced network dysfunction on CMOS-MEAs for neurotoxicity and rescue studies.Soluble and mature amyloid fibrils in drusen depositsSecreted human amyloid precursor protein binds semaphorin 3a and prevents semaphorin-induced growth cone collapse.Mechanistic investigation of the inhibition of Abeta42 assembly and neurotoxicity by Abeta42 C-terminal fragmentsRNA oxidation adducts 8-OHG and 8-OHA change with Aβ42 levels in late-stage Alzheimer's diseaseMysterious oligomerization of the amyloidogenic proteinsStaging of Alzheimer's pathology in triple transgenic mice: a light and electron microscopic analysis.Characterization of the interaction of β-amyloid with transthyretin monomers and tetramers.Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for Aβ accumulation in AD brainFluctuation methods to study protein aggregation in live cells: concanavalin A oligomers formationActivation of D1/D5 dopamine receptors protects neurons from synapse dysfunction induced by amyloid-beta oligomersAmyloid fiber formation and membrane disruption are separate processes localized in two distinct regions of IAPP, the type-2-diabetes-related peptide.Rescue of amyloid-Beta-induced inhibition of nicotinic acetylcholine receptors by a peptide homologous to the nicotine binding domain of the alpha 7 subtype.Proteasome degradation of brain cytosolic tau in Alzheimer's disease.Insight into amyloid structure using chemical probes.Butyrylcholinesterase interactions with amylin may protect pancreatic cells in metabolic syndrome.The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease.How the Wnt signaling pathway protects from neurodegeneration: the mitochondrial scenarioSoluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer's disease
P2860
Q24313479-2B49E581-04F0-45FC-8933-670475161969Q24633016-54F4AA46-A6AD-4ABA-A0FC-40746B6510BDQ26827066-457F0A5A-21DC-460B-9ADB-4F5499C21914Q26996487-AF36642F-8F22-4C1D-BB48-28BA26A60D89Q27001244-2DDAEF11-7A9F-4A18-844F-D01D01451E68Q27025120-054D752C-8E9F-4276-9C6B-FF4FBADD6F2EQ27653951-11C49B82-A215-4CEF-AE71-AAA539DE96E9Q27658538-F09C1CED-113A-4F0C-B3C1-D0262DA4BDCDQ28076932-9D4B1AF9-FFB4-42F1-B877-DB9A48B21816Q28301666-AB7E3C3E-1DEB-4C82-841D-989031E03D9CQ28308082-5DE7B342-509A-4D80-ADA1-02420282133AQ28479210-9C043A8C-1A89-4C13-AB2B-DE2DF1F38D4FQ28482893-823CDDD5-8960-4662-8307-71511D78B980Q28484767-75F6575F-B8AB-4239-8A67-AA969E8F74A7Q29977753-F48FC112-2259-4887-815F-19D28D0399F7Q30009839-951A127B-E21E-410C-8445-59B78F055D1FQ30627148-1ED0970E-2AA3-4ABF-81D8-B7DB55DEA2B5Q33408783-14ED5617-4DCF-40B2-98C5-1C678ED19E1FQ33470654-EE61433A-7080-455A-ADBF-CC6D6418B848Q33675254-C772D74B-A06C-4228-967D-170382F9D35FQ33716773-110B1EFE-76EF-400E-A08C-0C1BA5B20FC6Q33732756-747DF245-BE6F-4624-B14D-2C1A06001026Q33735695-2368EA3B-B0D1-46CE-9B03-FF45F48A6324Q33988005-5D7C41BB-67FB-4294-B2D1-67AFDD77DDC9Q34029566-81545568-3854-4C01-A7FD-CE5897AD2308Q34031631-B4D76A8D-CE0B-419F-A1BE-6FBFE2C38375Q34046583-BE4BBBD3-AA1D-486F-97A9-E48CDB7C4CC7Q34078130-6B19997A-FDEB-4E87-ACEF-3F82053E3EFCQ34146589-42F411C3-8CE2-4994-B5F8-6EC4CBD6AFA0Q34268519-75D5F769-BA28-450D-BEB7-6E3D5FF2DC0EQ34536409-A4543F6A-5AE9-4EDC-A4A5-D0C2DD542456Q34536809-F90E6C68-D7E0-47B6-AFF4-BAD6F0E2DAB6Q34774742-F82678E7-36ED-4CE9-8772-3AD1CA1588FDQ34872425-EF10A938-BD2B-4213-B428-C62FF70728BDQ34976438-976789EE-4F83-46C0-928A-B1218AAC86A2Q34990429-1A966ADE-5E13-478E-B458-1B6B5D16C35FQ35216136-3C4B8918-7916-41DF-AB83-FB2507D2388AQ35327219-D8D9CF72-27D6-437D-A170-466F7F8B691EQ35569964-21ACF01B-128A-4897-8FF1-12ED4166E939Q35643397-92A9D126-60B3-44BC-B3ED-BBE1C145622B
P2860
Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases.
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases.
@ast
Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases.
@en
Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases.
@nl
type
label
Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases.
@ast
Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases.
@en
Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases.
@nl
prefLabel
Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases.
@ast
Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases.
@en
Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases.
@nl
P1433
P1476
Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases
@en
P2093
Fernanda G De Felice
Sergio T Ferreira
P304
P356
10.1080/15216540701283882
P577
2007-04-01T00:00:00Z